Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Immix Biopharma, Inc. < Previous 1 2 Next > Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis December 19, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis December 16, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024 December 10, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media December 09, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients November 25, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2 October 02, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board September 19, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 August 28, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201 July 08, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum June 17, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma April 29, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma on Track to Dose NXC-201 Patients in United States April 18, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial March 20, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative March 05, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock February 08, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis February 07, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock February 05, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Announces Proposed Public Offering of Common Stock February 05, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products January 24, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board January 04, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board December 18, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023 December 11, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit November 30, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis November 22, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing November 21, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients November 06, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients November 06, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board October 26, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site October 16, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting October 03, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX < Previous 1 2 Next > Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
